Biomarin Pharmaceutical Inc. (BMRN)
NASDAQ
66.70
-0.98 (-1.45%)
Closed
Aug 21, 2026
Day's Range
66.5268.34
52 wk Range
49.2670.98
Financial Statements - BMRN - Biomarin Pharmaceutical Inc.
Revenue
3.22B▲ 12.9%
Net Income
348.90M▼ 18.3%Net Margin 10.8%
EBITDA
572.93M▼ 10.6%
Free Cash Flow
717.01M▲ 50.8%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 3.22B | 2.85B | 2.41B | 2.09B | 1.84B | 1.86B |
| Cost of Goods | 717.44M | 580.23M | 514.85M | 483.66M | 470.51M | 524.27M |
| Gross Profit | 2.50B | 2.27B | 1.90B | 1.61B | 1.37B | 1.33B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 409.49M | 474.19M | 158.09M | 45.96M | -74.33M | -91.83M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 8.99M | 5.33M | -10.53M | 101.55M | 3.84M | 55.46M |
| Pre Tax Income | 482.48M | 541.76M | 188.56M | 149.57M | -75.35M | -48.99M |
| Income Tax | 133.57M | 114.90M | 20.91M | 8.01M | -11.27M | -903.02M |
| Net Income | 348.90M | 426.85M | 167.64M | 141.56M | -64.08M | 854.02M |
| EPS Basic | 1.82 | 2.25 | 0.89 | 0.76 | -0.35 | 4.75 |
| EPS Diluted | 1.8 | 2.21 | 0.87 | 0.75 | -0.35 | 4.53 |
| Basic Shares Outstanding | 191.78M | 190.02M | 187.83M | 185.26M | 182.85M | 180.80M |
| Diluted Shares Outstanding | 191.78M | 190.02M | 187.83M | 185.26M | 182.85M | 180.80M |
| Ebit | 493.37M | 554.10M | 205.30M | 164.95M | -60.60M | -21.51M |
| Ebitda | 572.93M | 640.52M | 309.69M | 163.32M | 55.43M | 35.33M |
| Net Income Continuous Operations | 348.90M | 426.85M | 167.64M | 141.56M | -64.08M | 854.02M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
